

FACT SHEET

COMPANY PROFILE


Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX and SDax of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 3,232 employees (as of 30 September 2019) worldwide, the Group generated revenue of EUR 1,459.3m in fiscal year 2018/19 (as of 30 September).

The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG's shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.

SHARE CHART



SHAREHOLDER STRUCTURE



MANAGEMENT BOARD



Dr. Ludwin Monz
CEO



Justus Felix Wehmer
CFO



Jan Willem de Cler

SUPERVISORY BOARD

- > Prof. Dr. Michael Kaschke
- > Dr. Christian Müller
- > Dr. Karl Lamprecht
- > Cornelia Grandy
- > Jeffrey Marx
- > Tania von der Goltz
- > Dr. Markus Guthoff
- > Isabel De Paoli
- > René Denner

STOCK FUNDAMENTALS

ISIN	DE0005313704
WKN	531370
Share type	Ordinary
Bloomberg Code	AFX@GR
Reuters Code	AFXG.DE
Ticker	AFX
Branch	Medical Technology
Index	MDAX, TecDAX
Segment	Prime Standard
Last Dividend	0.65 EUR (2018/19)
No. of shares	89,440,570
Market Cap	EUR 10.84 bn
52 week high	140.50 EUR
52 week low	67.70 EUR

FINANCIAL CALENDAR

May 10, 2021	Publication half-yearly financial report
May 27, 2021	Annual General Meeting
Aug 06, 2021	Publication quarterly statement (call-date Q3)
Dec 10, 2021	Publication annual financial report

FACT SHEET

HIGHLIGHTS ON A YEARLY BASIS¹

	2019/20		2018/19		2017/18	
	€m	%	€m	%	€m	%
Revenue	1,335.5	100	1,459.3	100	1,280.9	100
Research and development expenses	218.8	16.4	173.3	11.9	159.6	12.5
EBIT	177.6	13.3	264.7	18.1	197.1	15.4
Consolidated profit ¹	123.4	9.2	160.6	11.0	126.2	9.9
Earnings per share ² (in €)	1.37		1.79		1.41	
Dividend per share (in €)	0,50 ³		0.65		0.55	
Cash flows from operating activities	178.5		219.6		187.2	
Cash flows from investing activities	(71.9)		(145.8)		(28.9)	
Cash flows from financing activities	(123.0)		(58.6)		(157.2)	
Total assets	2,013.3	100	2,022.1	100	1,662.1	100
Property, plant and equipmen	135.3	6.7	116.8	5.8	62.6	3.8
Equity	1,450.6	72.0	1,417.0	70.1	1,314.6	79.1
Net cash ⁴	707.2	35.1	677.8	33.5	670.0	40.3
Employees at end of reporting period (30 September)	3,290		3,232		3,048	

1 Before non-controlling interests

2 Profit/(loss) per share attributable to the shareholders of the parent company in the fiscal year

3 Amount proposed by the Supervisory Board and the Management Board of Carl Zeiss Meditec AG

4 Cash and cash equivalents plus treasury receivables from/payables to the treasury of Carl Zeiss AG

Carl Zeiss Meditec AG

Göschwitzer Str. 51-52
07745 Jena
Deutschland
www.zeiss.de/meditec-ag/ir

investors.meditec@zeiss.com

Contact Investor Relations

Sebastian Frericks
Director Investor Relations
Phone: +49 (0) 36 41 / 2 20 -1 16
Fax: +49 (0) 36 41 2 20 - 1 17
E-Mail: investors.meditec@zeiss.com